Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is 2.93%. On last trading day company shares ended up $13.69. Analysts mean target price for the company is $35.50. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -10.01%.
GTx, Inc. (NASDAQ:GTXI) announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy. The clinical data is being presented during the Breast Cancer-HER2/ER poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. GTx, Inc. (NASDAQ:GTXI) shares fell -14.46% in last trading session and ended the day on $1.42. GTXI gross Margin is – and its return on assets is -151.90%.GTx, Inc. (NASDAQ:GTXI) quarterly performance is -15.48%.
Dendreon Corporation (NASDAQ:DNDN) held its 2014 Annual Meeting of Stockholders on May 15, 2014 at the Bridgewater Marriott, 700 Commons Way, Bridgewater, New Jersey 08807. A total of 160,055,271 shares of the Company’s common stock were entitled to vote as of April 2, 2014, the record date for the Annual Meeting, of which 121,494,231 (75.91%) were present in person or by proxy at the Annual Meeting. Dendreon Corporation (NASDAQ:DNDN) shares moved down -6.48% in last trading session and was closed at $2.02, while trading in range of $2.02 – $2.19. Dendreon Corporation (NASDAQ:DNDN) year to date (YTD) performance is -32.44%.
Shares of Puma Biotechnology Inc. (NYSE:PBYI) , a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer, plunged as much as 25% after reporting phase 2 data on PB272 (also known as neratinib) at the American Society for Clinical Oncology’s annual meeting over the weekend. Puma Biotechnology Inc. (NYSE:PBYI) ended the last trading day at $57.06. Company weekly volatility is calculated as 7.93% and price to cash ratio as 8.76.Puma Biotechnology Inc. (NYSE:PBYI) showed a negative weekly performance of -24.12%.
Clovis Oncology Inc. (NASDAQ:CLVS) stock is down nearly 8% yesterday fter it was announced that Clovis Oncology’s (CLVS) lung cancer drug CO-1686 may be turning patients into diabetics. Clovis Oncology Inc. (NASDAQ:CLVS) weekly performance is -16.23%. On last trading day company shares ended up $47.75. Analysts mean target price for the company is $98.63. Clovis Oncology Inc. (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -19.50%.